Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

NCT00396240 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00396240
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00396240 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals
Lead sponsor
AstraZeneca
Phase
Phase 4
Overall status
Withdrawn
Start date
February 28, 2002
Completion date
Not reported
Enrollment
1,294
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

primary hypercholesterolaemia